Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial
Authors:
- Stevo JuliusSJStevo Julius
- Giuseppe ManciaGMGiuseppe Mancia
- Gordon T McInnesGMGordon T McInnes
- Tsushung HuaTHTsushung Hua
- Michael A WeberMWMichael A Weber
- Antonio CocaACAntonio Coca
- Steffan EkmanSESteffan Ekman
- Xavier GirerdXGXavier Girerd
- Kenneth JamersonKJKenneth Jamerson
- Pierre LarochellePLPierre Larochelle
- Thomas M MacDonaldTMThomas M MacDonald
- 1 July 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 24 (7) , 1405-1412
Abstract
Type 2 diabetes is emerging as a major health problem, which tends to cluster with hypertension in individuals at high risk of cardiovascular disease. To test for the first time the hypothesis that treatment of hypertensive patients at high cardiovascular risk with the angiotensin-receptor blocker (ARB) valsartan prevents new-onset type 2 diabetes compared with the metabolically neutral calcium-channel antagonist (CCA) amlodipine. Pre-specified analysis in the VALUE trial. Follow-up averaged 4.2 years. The risk of developing new diabetes was calculated as an odds ratio (OR) with 95% confidence intervals (CI) for different definitions of diabetes. A sample of 9995 high-risk, non-diabetic hypertensive patients. Valsartan or amlodipine with or without add-on medication [hydrochlorothiazide (HCTZ) and other add-ons, excluding other ARBs, angiotensin-converting enzyme (ACE) inhibitors, CCAs]. New diabetes defined as an adverse event, new blood-glucose-lowering drugs and/or fasting glucose > 7.0 mmol/l. New diabetes was reported in 580 (11.5%) patients on valsartan and in 718 (14.5%) patients on amlodipine (OR 0.77, 95% CI 0.69–0.87, P < 0.0001). Using stricter criteria (without adverse event reports) new diabetes was detected in 495 (9.8%) patients on valsartan and in 586 (11.8%) on amlodipine (OR 0.82, 95% CI 0.72–0.93, P = 0.0015). Compared with amlodipine, valsartan reduces the risk of developing diabetes mellitus in high-risk hypertensive patients.Keywords
This publication has 34 references indexed in Scilit:
- Global burden of hypertension: analysis of worldwide dataThe Lancet, 2005
- Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetesThe American Journal of Cardiology, 2005
- Global burden of hypertension: analysis of worldwide dataThe Lancet, 2005
- Adverse Prognostic Significance of New Diabetes in Treated Hypertensive SubjectsHypertension, 2004
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- Global and societal implications of the diabetes epidemicNature, 2001
- Characteristics of 15314 Hypertensive Patients at High Coronary Risk. The VALUE TrialBlood Pressure, 2001
- The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) Trial of Cardiovascular Events in Hypertension. Rationale and DesignBlood Pressure, 1998
- The hemodynamic link between insulin resistance and hypertensionJournal Of Hypertension, 1991
- The epidemiology of impaired glucose tolerance and hypertensionAmerican Heart Journal, 1991